Skip to search formSkip to main contentSkip to account menu

ICRF-187

Known as: ICRF 187, ICRF187 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

DexrazoxaneDexrazoxane hydrochloride
Zinecard

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits
SummaryThe long-term protective effect of ICRF-187 against chronic daunorubicin cardiotoxicity was examined. Rabbits were given 3… 
1998
1998
ICRF-187 (dexrazoxan) protects from adriamycin-induced nephrotic syndrome in rats.
BACKGROUND Reactive oxygen species produced during metabolism of adriamycin are purported to play an important role in the… 
Review
1997
Review
1997
Animal models of anthracycline cardiotoxicity: Basic mechanisms and cardioprotective activity
1995
1995
Doxorubicin reduces the iron(III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals.
Dexrazoxane (ICRF-187) is very effective in protecting against doxorubicin-induced cardiotoxicity. Dexrazoxane likely acts though… 
1993
1993
Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells.
Mitoxantrone cardiotoxicity was investigated in isolated neonatal rat heart myocytes treated for 3 h in the presence or absence… 
1993
1993
Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187.
Histological and immunohistochemical studies using specific monoclonal antibodies were made to evaluate the severity of the… 
1993
1993
The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes
The ability of the cardioprotective agent ICRF-187 (dexrazoxane), its one-ring open hydrolysis products, and its two-ring open… 
1986
1986
Phase I study of ICRF-187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adults.
A phase I study of ICRF-187 as a 2-hour iv infusion daily for 3 days was conducted in 46 evaluable pediatric patients. The… 
Highly Cited
1985
Highly Cited
1985
Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles.
This investigation examined the potential of N-acetylcysteine (NAC) and ICRF-187, alone and in combination, to protect against… 
Highly Cited
1983
Highly Cited
1983
Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine.
: Studies were made of the potential of vitamin E and ICRF-187 to protect against the cardiotoxicity resulting from chronic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)